Detalhe da pesquisa
1.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427411
2.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407545
3.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31365801
4.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
Blood
; 134(2): 111-122, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023700
5.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Br J Haematol
; 184(4): 558-569, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30506764
6.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica
; 104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923097
7.
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019.
J Natl Compr Canc Netw
; 17(5): 414-423, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085755
8.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 17(6): 721-749, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200351
9.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Blood
; 128(25): 2899-2908, 2016 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27802969
10.
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol
; 93(11): 1402-1410, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129285
11.
Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
Future Oncol
; 14(22): 2265-2277, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29569483
12.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450857
13.
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Blood
; 125(16): 2497-506, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25700432
14.
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
Blood
; 126(25): 2686-94, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472751
15.
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
J Natl Compr Canc Netw
; 15(9): 1091-1102, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28874594
16.
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(7): 926-957, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28687581
17.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Lancet Oncol
; 17(10): 1409-1418, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27637985
18.
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 173(2): 253-9, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27040320
19.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 369(1): 32-42, 2013 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782158
20.
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Blood
; 123(22): 3398-405, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615778